Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.7252W HIGH $16.67
Volume
289.94 K
Value Traded
6.98 M
Short % Float
4.9%
+0.57%Week
-4.63%1 Month
-6.2%3 Month
+1.57%6 Month
-66.07%5 Year
+103.56%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
816.80 M
EPS (TTM)
1.38
P/E Ratio
10.32
Ent. Value
338.22 M
Total Shares
57.51 M
Float Shares
48.11 M
Insiders
16.39%
Institutions
52.59%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
INMD Catalyst Timeline
Dated clinical, regulatory and corporate events for InMode Ltd.
Past FDA Catalysts and PDUFA Decisions
How INMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
InMode Ltd. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every INMD program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| KRENSAVAGE ASSET MANAGEMENT, LLC | 0.7 % (16.7 %) | 1.77 M | 120.94 K |
INMD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INMD ranks across every disease it competes in
Competitive Position is a premium feature
See how INMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINMD News
INMDInMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool
InMode Ltd. has launched Morpheus8 Cool, an advanced version of its RF microneedling technology. This new product, available on the Morpheus8MAX platform, enhances treatment comfort and precision with its Cool Comfort Technology. The device allows practitioners to choose between Guided and Manual modes, catering to individual patient needs. The introduction of Morpheus8 Cool has received enthusiastic feedback from providers, indicating strong demand in the aesthetics market.
Read more →INMDInMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025
InMode Ltd. reported its financial results for Q2 2026, showing consistent revenues of $95.6 million compared to the same period in 2025. The company experienced a 13% increase in revenues from consumables and services, while its cash position stood at $501.1 million. However, both GAAP and non-GAAP operating margins saw declines due to rising costs and restructuring efforts.
Read more →INMDSteel Partners Urges InMode Shareholders to Vote AGAINST the Re-Election of Dr. Hadar Ron and AGAINST Extraordinary Special Committee Compensation at the July 30 Annual General Meeting
Steel Partners Holdings has called on InMode shareholders to oppose the re-election of Dr. Hadar Ron and to reject a proposal concerning special committee compensation at the upcoming Annual General Meeting. This move reflects Steel's significant stake and concerns about the company's governance. The letter emphasizes the need for shareholder action against these proposals.
Read more →INMDInMode to Report Second Quarter 2026 Financial Results on August 5, 2026, Expects Q2 Revenue Between $95.2M-$95.4M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
InMode Ltd. announced it will release its Q2 2026 financial results on August 5, 2026, with expected revenues between $95.2 million and $95.4 million. The company also reiterated its full-year revenue guidance of $365 million to $375 million. Due to ongoing evaluations of strategic proposals, InMode will not host an investor call or meetings at this time.
Read more →INMDInMode Confirms Receipt of Unsolicited Proposal
InMode Ltd. has confirmed the receipt of an unsolicited acquisition proposal from Steel Partners Holdings. The company's Board of Directors has established a Special Committee to review the proposal with its advisors. The Committee is focused on ensuring the best interests of shareholders during this evaluation process.
Read more →INMDInMode Appoints Dr. Shlomo Nass as Chairman of the Board and Moshik Itzkovich as Chief Financial Officer
InMode Ltd. has appointed Dr. Shlomo Nass as the new Chairman of the Board and Moshik Itzkovich as Chief Financial Officer. Dr. Nass succeeds Dr. Michael Anghel, who recently retired, while Itzkovich takes over from Yair Malca. Both appointments are expected to enhance the company's governance and financial strategies.
Read more →INMDInMode to Present at Upcoming Investor Conferences and Events
InMode Ltd. announced its participation in upcoming investor conferences, including a virtual bus trip and an in-person fireside chat at the Jefferies Global Healthcare Conference. Presenters will include Yair Malca, the outgoing CFO, and Moshik Itzkovich, Senior VP of Finance. The events aim to engage investors and discuss InMode's innovative medical technologies.
Read more →INMD▼ -5.6%on this news
InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase
InMode Ltd. reported its financial results for the first quarter of 2026, showing a 5% increase in GAAP revenue to $82 million compared to the previous year. However, the company experienced a decline in net income and operating margins. The firm maintains a strong cash position and has initiated a share repurchase program, signaling confidence in its future performance despite macroeconomic challenges.
Read more →INMDInMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
InMode Ltd. has announced its expectations for the first quarter of 2026 financial results, projecting revenue between $81.5 million and $81.7 million. The company also anticipates a non-GAAP gross margin of 75% to 76%. Furthermore, InMode has reiterated its full-year revenue guidance for 2026, estimating between $365 million and $375 million. A conference call is scheduled for May 6, 2026, to discuss these results.
Read more →INMDInMode to Present at the 25th Annual Needham Virtual Healthcare Conference
InMode Ltd. announced its participation in the 25th Annual Needham Virtual Healthcare Conference, where CEO Moshe Mizrahy and CFO Yair Malca will present. The presentation is scheduled for April 13, 2026, and will be moderated by Michael Matson. Additionally, InMode will conduct virtual one-on-one investor meetings on the same day.
Read more →INMD▲ +6.1%on this news
InMode Announces New Share Repurchase Program
InMode Ltd. has announced a new share repurchase program, allowing the company to buy back approximately 10% of its outstanding shares, totaling around 6.38 million shares. The decision comes after the company successfully repurchased $127.4 million in shares in 2025. InMode aims to utilize its strong cash flow for these repurchases while continuing to assess future capital allocation opportunities.
Read more →INMD▼ -6.7%on this news
InMode Announces Conclusion of Independent Transaction Committee Review
InMode Ltd. has concluded its independent transaction committee review, determining that none of the proposals received were adequate for the company's interests. The committee has decided to discontinue the review process and will focus on evaluating its business and growth strategies. No additional updates will be shared unless deemed necessary.
Read more →INMDInMode Reports Fourth Quarter and Full Year 2025 Financial Results: Quarterly GAAP Revenue of $103.9 Million and Full Year Revenue of $370.5 Million
InMode Ltd. reported its fourth quarter and full year 2025 financial results, showing a quarterly revenue increase of 6% to $103.9 million, while full year revenue decreased by 6% to $370.5 million. The company highlighted a strong cash position and plans to launch new products in 2026. Despite challenges in the industry, early signs of stabilization were noted, particularly in Europe.
Read more →INMDInMode to Participate in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference
InMode Ltd. announced its participation in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference. CFO Yair Malca will host investor meetings on February 11, 2026, in Snowbird, Utah. Interested investors can schedule meetings through BTIG sales representatives.
Read more →INMD▲ +5.8%on this newsshared move
InMode Responds to Transaction Rumors
InMode Ltd. has acknowledged recent market rumors about a non-binding acquisition proposal by Steel Partners Holdings L.P. The company is currently reviewing strategic alternatives through a committee of independent directors. While they have retained legal and financial advisors, there is no guarantee of a transaction or outcome from this review process.
Read more →INMD▼ -8.8%on this news
InMode to Report Fourth Quarter & Full Year 2025 Financial Results and Hold Conference Call on February 10, 2026, Expects Q4 Revenue Between $103.6M-$103.8M
InMode Ltd. anticipates releasing its financial results for Q4 and full year 2025 on February 10, 2026. Preliminary estimates suggest Q4 revenue will range from $103.6 million to $103.8 million, with full year revenue expected between $370.2 million and $370.4 million. The company will hold a conference call to discuss these results, featuring key executives.
Read more →INMDInMode Reports Third Quarter 2025 Financial Results: Quarterly Revenue of $93.2 Million, 78% Gross Margins
InMode Ltd. reported its third quarter 2025 financial results, showing a revenue of $93.2 million, down from $130.2 million in the same quarter of 2024. The company experienced a 26% increase in revenues from consumables and services, but overall net income fell significantly. Management remains optimistic despite challenging economic conditions and has appointed a new President for North America.
Read more →INMDInMode Appoints Michael Dennison as President of North America
InMode Ltd. has appointed Michael Dennison as President of North America, promoting him from Vice President of Sales. Dennison brings nearly a decade of experience at InMode and a strong background in the aesthetic medical device industry. His leadership is expected to drive revenue growth and strengthen the company's market position in North America.
Read more →INMDInMode to Participate in Upcoming Investor Conferences
InMode Ltd. has announced its participation in several upcoming investor conferences in November 2025. Key presentations will be made by CFO Yair Malca and CEO Moshe Mizrahy at events including the UBS Global Healthcare Conference and Jefferies Global Healthcare Conference. These conferences will provide opportunities for one-on-one meetings and discussions about InMode's innovative medical technologies.
Read more →About InMode Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next INMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime